<DOC>
	<DOCNO>NCT02161406</DOCNO>
	<brief_summary>The study hypothesis SC abatacept safe show evidence efficacy ( improvement modify Rodnan score [ mRSS ] ) patient diffuse cutaneous systemic sclerosis ( dcScc ) compare match placebo .</brief_summary>
	<brief_title>A Study Subcutaneous Abatacept Treat Diffuse Cutaneous Systemic Sclerosis</brief_title>
	<detailed_description>This study randomize placebo-controlled double-blind phase 2 trial patient dcSSc . Eligible participant randomize 1:1 ratio either 125 mg SC abatacept match placebo , stratify duration dcSSc disease duration ( &lt; 18 month vs &gt; 18 &lt; /=36 month ) . Study participant treat 12 month double-blind study medication , follow additional 24 week open-label SC abatacept therapy . 86 patient randomize approximately 35 center US , Canada Europe , goal analyze 74 participant . The investigator study test whether abatacept statistically superior placebo reduce MRSS month 12 explore ability abatacept prevent reverse progression patient early disease duration lower MRSS score , reverse establish disease patient longer disease duration high MRSS score .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Diagnosis Systematic Sclerosis ( SSc ) , define use 2013 American College Rheumatology/ European Union League Against Rheumatism classification SSc 2 . Diffuse Systemic Sclerosis ( dcSSc ) define LeRoy Medsger 3 . Disease duration ≤ 36 month ( defined time first non−Raynaud phenomenon manifestation ) 4 . For disease duration ≤ 18 month : ≥ 10 ≤ 35 mRSS unit screen visit 5 . For disease duration &gt; 1836 month : ≥ 15 ≤ 45 mRSS unit screen visit one following : Increase ≥ 3 mRSS unit compare last visit within previous 16 month Involvement one new body area ≥ 2 mRSS unit compare last visit within previous 16 month Involvement two new body area ≥ 1 mRSS unit compare last visit within previous 16 month Presence 1 Tendon Friction Rub 6 . Age ≥ 18 year screen visit 7 . If female childbearing potential , patient must negative pregnancy test screen baseline visit 8 . Oral corticosteroid ( ≤ 10 mg/day prednisone equivalent ) NSAIDs permit patient stable dose regimen 2 week prior include baseline visit . 9 . ACE inhibitor , calciumchannel blocker , protonpump inhibitor , and/or oral vasodilator permit patient stable dose ≥ 2 week prior include baseline visit . 1 . Rheumatic disease dcSSc ; acceptable include patient fibromyalgia sclerodermaassociated myopathy 2 . Limited cutaneous systemic sclerosis sine scleroderma screen visit 3 . Major surgery ( include joint surgery ) within 8 week prior screen visit 4 . Infected ulcer prior randomization 5 . Treatment investigational agent within ≤ 4 week ( 5 halflives investigational drug , whichever long ) baseline visit 6 . Previous treatment celldepleting therapy , include investigational agent , include limited , CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 , ABA 7 . AntiCD20 , cyclophosphamide within 12 month prior baseline visit . 8 . Use Intravenous Immunoglobulin ( IVIG ) within 12 week prior baseline visit 9 . Previous treatment chlorambucil , bone marrow transplantation , total lymphoid irradiation 10 . Immunization live/attenuated vaccine within ≤ 4 week prior baseline visit 11 . Treatment methotrexate , hydroxychloroquine , cyclosporine A , azathioprine , mycophenolate mofetil rapamycin , colchicine , Dpenicillamine , within≤ 4 week prior baseline visit 12 . Treatment etanercept within ≤ 2 week , infliximab , certolizumab , golimumab , ABA adalimumab within ≤ 8 week , anakinra within ≤ 1 week prior baseline visit 13 . Pulmonary disease FVC ≤ 50 % predict , DLCO ( uncorrected hemoglobin ) ≤ 40 % predict screen visit 14 . Pulmonary arterial hypertension ( PAH ) determine right heart catheterization PAH approve medication PAH . It acceptable use PDFE5 inhibitor Raynaud 's digital ulcer . 15 . Subjects risk tuberculosis ( TB ) . Specifically exclude study participant history active TB within last 3 year , even treat ; history active TB great 3 year ago , unless documentation prior antiTB treatment appropriate duration type ; current clinical , radiographic , laboratory evidence active TB ; latent TB successfully treat ( ≥ 4 week ) . 16 . Positive hepatitis B surface antigen prior baseline visit 17 . Positive hepatitis C antigen , presence hepatitis C virus also show polymerase chain reaction recombinant immunoblot assay prior baseline visit 18 . Subjects risk tuberculosis ( TB ) . Specifically exclude study participant history active TB within last 3 year , even treat ; history active TB great 3 year ago , unless documentation prior antiTB treatment appropriate duration type ; current clinical , radiographic , laboratory evidence active TB ; latent TB successfully treat ( ≥ 4 week ) . 19 . Any following screening visit : Hemoglobin &lt; 8.5 g/dL ; WBC &lt; 3,000/mm3 ( &lt; 3 x 109/L ) ; platelet &lt; 100,000/mm3 ( &lt; 3 x 109/L ) ; serum creatinine &gt; 2 x ULN ; serum ALT AST &gt; 2 x ULN 20 . Severe skin thickening ( mRSS 3 ) inner aspect thighs , upper arm , abdomen 21 . Patients history anaphylaxis abatacept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Scleroderma</keyword>
</DOC>